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Non-competitive cyclic peptides for targeting enzyme–substrate 
complexes
Cyclic peptides are promising affi  nity reagents for studying 
protein–protein interactions. A series of cyclic peptides were 
identifi ed using the mRNA display-based RaPID method that 
are selective for the human hypoxia inducible factor prolyl 
hydroxylases (PHDs) – enzymes crucial in hypoxia sensing. 
Biophysical analyses reveal the cyclic peptides bind tightly, 
away from the enzyme active site. This enables conservation 
of catalysis and substrate binding, allowing capture of not only 
the PHDs, but also their primary substrate, hypoxia inducible 
factor HIF1α.
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Affinity reagents are of central importance for selectively identifying proteins and investigating their
interactions. We report on the development and use of cyclic peptides, identified by mRNA display-
based RaPID methodology, that are selective for, and tight binders of, the human hypoxia inducible
factor prolyl hydroxylases (PHDs) – enzymes crucial in hypoxia sensing. Biophysical analyses reveal the
cyclic peptides to bind in a distinct site, away from the enzyme active site pocket, enabling conservation
of substrate binding and catalysis. A biotinylated cyclic peptide captures not only the PHDs, but also their
primary substrate hypoxia inducible factor HIF1-a. Our work highlights the potential for tight, non-active
site binding cyclic peptides to act as promising affinity reagents for studying protein–protein interactions.Introduction
In investigating the distribution and roles of proteins,
researchers oen use antibodies, both for identifying proteins
and in dening their interactions. Although antibodies are
powerful reagents, they can have limitations, including their
large size, oen poorly-characterised binding modes/affinities,
reproducibility issues arising from batch variations, high
costs and the use of animals (where immunisation methods are
used). Collectively these issues mean antibody-based results are
oen qualitative and can sometimes give misleading results in
protein–protein interaction (PPI) studies,1 e.g. when the anti-
body blocks a relevant binding interaction. Signicant efforts
have thus been made to develop improved antibodies (e.g.
antibody fragments from phage-display,2,3 and nanobodies4) or
to develop protein/chemical alternatives (non-immunoglobulinford, Chemistry Research Laboratory, 12
il: akane.kawamura@chem.ox.ac.uk
of Auckland, Private Bag 92019, Auckland
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iffe Department of Medicine, University of
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tion (ESI) available. See DOI:
ersity of Auckland, Private Bag 92019,
hemistry 2018protein5 and peptide6,7 scaffolds, nucleic acid e.g. aptamers,8,9
and inhibitor-based chemical approaches10) to address the
demand for reliable protein-binding reagents, both for research
and clinical applications. The non-antibody affinity reagents
offer improved reproducibility (e.g. when produced in vitro or by
chemical synthesis), high affinity, and precise targeting. In
practice, however, they have not replaced conventional anti-
bodies, which are nding new applications, e.g. in proteomics.
Genetically encoded peptide screening technologies have
emerged as methods that can efficiently generate protein binders
with high affinity and selectivity.11–14 The mRNA display based
cyclic peptide (CP) generation and screening platform – Random
nonstandard Peptide Integrated Discovery (RaPID) - has been
applied to enzymes in various pathways and transcriptional
regulation (e.g. membrane transporters,15 receptors,16 ubiquitin
ligases,17 kinases,18 deacetylases,19 histone demethylases20).
Inspired by these results, we were interested to investigate
whether CPs generated from ‘RaPID’ selection can be developed
as affinity probes. Our enzyme target was the prolyl hydroxylase
isoform 2 (PHD2), a hypoxia sensor, which plays a central role in
the human hypoxic response. PHDs catalyse hydroxylation of key
proline residues of hypoxia inducible factor HIF1-a in an oxygen-
dependent manner, which signals for its degradation via the
proteasomes21,22 (ESI Fig. 1†). PHD inhibitors are in clinical trials
for treatment of anaemia in chronic kidney disease (CKD),
because erythropoietin (EPO) is upregulated by HIF.23 While HIF-
a is the primary target of the PHDs, they have been reported to
associate with and/or and regulate other proteins. To date, vali-
dation of these PHD substrates/complexes has been somewhat
limited, in part, due to reproducibility issues with antibodies.
There is thus a demand for chemical tools targeting PHDs toChem. Sci., 2018, 9, 4569–4578 | 4569
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View Article Onlineidentify and validate such complexes. Our results reveal the effi-
ciency of the RaPID system for generating non-inhibitory, tight
binding CPs that bind away from the active site and that CPs can
be used for substrate–enzyme capture studies. Overall, the results
demonstrate that the RaPID system enables identication of CPs
that complement antibodies for use in protein research.Results
Identication of cyclic peptide binders of PHD2
We set out to investigate the potential of the RaPID system24 for
generating tight-binding CPs for human PHDs, using the catalytic
domain of PHD2 (residues 181–426, tPHD2) with N-terminal His-
tag and C-terminal biotinylation (tPHD2HisBio) (ESI Fig. 2†). An
mRNA library,18 which encodesN-chloroacetyl-DTyr (ClAc-DTyr) as
a reprogrammed initiator followed by 4–12 mer randomised
peptide sequences, a C-terminal cysteine, a linker and a stop
codon, was constructed as described.18 In vitro translation of the
puromycin-fused mRNA library gave an mRNA-displayed CP
library via spontaneous posttranslational formation of a thioether
linkage between the N-terminal ClAc-DTyr and the C-terminal Cys.
The library was applied to biotin-streptavidin beads to eliminate
non-specic binding sequences, and subsequently applied to
tPHD2HisBio-immobilised streptavidin beads. Recovery of target
binding species was monitored by qPCR of the complementary
DNA (cDNA), produced from a reverse transcription of the mRNA
recovered from the positive and the nal negative selection steps
in each round; the fraction of recovery was calculated relative to
the input library for the selection round. A signicant increase in
recovery (>5%) was observed aer the h round (R5) (ESI
Fig. 2†). The cDNA from R5 was cloned into pGEMT-Easy vector
and transformed into E. coli. Sequencing of 19 colonies resulted
in six unique peptide sequences (PHD2_1–PHD2_6), with
PHD2_4 appearing with the highest frequency (13/19) (Fig. 1A).
Next generation sequencing (NGS) was used to analyse the pop-
ulation distribution of the CP encoding sequences of the fourth
(R4) and h (R5) selection rounds (Fig. 1). The results were in
accord with the colony selection results, but revealed a higher
diversity of sequences (these sequences were typically in low
abundance, (<0.1% of the total reads)). The most abundant R5 14
mer sequences were used to generate a Logo plot (Fig. 1B, ESI
Table 1†),25 revealing a common motif with a Trp towards the N-Fig. 1 Cyclic peptides identified using the RaPID screening platform aga
identified from the colony sequencing (R5) and corresponding next gene
are indicated as % of the total reads. (B) Logo plot analyses of NGS sequen
different peptides). The ‘first’ ring residue is DTyr and the ‘last’ ring residu
4570 | Chem. Sci., 2018, 9, 4569–4578terminus and a highly conserved “TFYLSR” motif (where X
represents any amino acid) at the C-terminus.
Characterisation of cyclic peptide hits against PHD2
The top ve abundant CP sequences were prepared by solid
phase peptide synthesis without the (GlySer)3 linker (ESI Table
2†), and their affinities for tPHD2HisBio investigated using biol-
ayer interferometry (BLI) with C-terminal biotin immobilisation
(Fig. 2, ESI Fig. 3†). All ve CPs bound to tPHD2HisBio with
nanomolar to sub-nanomolar KD values, while the PHD2 cognate
substrate C-terminal oxygen dependent domain (CODD), a frag-
ment peptide of HIF1-a, bound with KD¼ 5.2 0.5 mMunder the
same conditions (similar to the reported surface plasmon reso-
nance value,26 Fig. 3D). In particular, 3C and 4C (derived from
PHD2_3 and PHD2_4 respectively) were the highest affinity
binders, with KD values of 270 pM and 170 pM, and dissociative
half-lives t1/2 of 68 min and 134 min, respectively. Similar KD
values were obtained using N-terminal His-tag immobilisation
(ESI Fig. 4†). The CPs were then tested for binding to represen-
tative other human 2OG oxygenases: FIH, a related HIF hydrox-
ylating 2OG oxygenase and KDM4A, a histone demethylase (Fig. 2
and ESI Fig. 5†). CPs showed very weak binding (if any), with 3C
showing almost no detectable binding. Since PHD2 catalyses the
hydroxylation of Pro residues of HIF, the CP sequences contain-
ing Pro (4C, 5C, 6C) were tested as PHD2 substrates; however no
enzymatic oxidation was observed (ESI Fig. 6†). All ve CPs were
tested as inhibitors of CODD hydroxylation but none showed
signicant effects at >1000 fold excess of the KD (Fig. 2D),
implying the peptides do not bind at the active site.
Cyclic peptides do not affect HIF peptide binding to PHD2
To investigate the binding regions of the CPs to tPHD2, NMR
assays were conducted. Titrations of the highest affinity CPs (3C
& 4C) into labelled tPHD2 (181–402, non-tagged) with moni-
toring by 1H–15N HSQC showed modest changes in the back-
bone amide chemical shis of some residues indicating that the
peptide is interacting with the protein without disrupting its
overall fold (Fig. 3A and B). Comparison of the assigned apo-
tPHD2 NMR spectrum27 of tPHD2 with CPs using nearest
neighbour assignment showed that both CPs interact with
tPHD2 in the same regions (Fig. 3, ESI Fig. 7E†). While the
double-stranded b-helix (DSBH, b strands I to VIII) core fold,inst tPHD2. (A) Sequences of cyclic peptides obtained. The sequences
ration sequencing (NGS) data analysis for cDNA pools from R4 and R5
cing data for R5 for 14 mer sequences present at a level of$0.01% (256
e is Cys for all sequences.
This journal is © The Royal Society of Chemistry 2018
Fig. 2 Characterisation of CP hits. Biolayer interferometry traces for association and dissociation phases of binding for 3C (A) and 4C (B) to
tPHD2 (top) and other representative 2OG-oxygenases (FIH (middle) and KDM4A (bottom)), with raw (coloured) and fitted (black) curves shown.
(C) BLI KD values for CP binding to tPHD2, as determined by global fitting of the data with  representing the standard error. Full traces for all
peptides are in ESI Fig. 3.† (D) MALDI-TOF MS based PHD2 inhibition assays with representative spectra (LHS) showing CODD hydroxylation
(+16 Da peak). (RHS) Bar chart showing the normalised activity of tPHD2 (1 mM) relative to a DMSO control (average stdev n¼ 3). CPs were used
at >4-fold excess of enzyme concentration. N-Oxalylglycine (NOG), a 2OG mimicking inhibitor of PHD2, is a positive inhibitor control (10 mM).
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View Article Onlinewhich supports the active site, is largely unaffected by CP
addition, the residues in and around b1/a3 (residues 206–215),
a4 (residues 268–270) and bV region of the DSBH (345–360)
exhibited substantial changes in the weighted chemical shi on
CP binding (Fig. 3B). When mapped onto an existing tPHD2
crystal structure (PDB 2G19) the weighted chemical shi
changes imply that the affected residues all lie on the same face
of the protein, in a relatively ‘at’ surface, opposite to the active
site pocket and the CODD substrate binding region (Fig. 3B).
Using 1H–15N HSQC NMR, we have previously shown that in
the presence of saturating HIF-1a CODD, signicant shis in the
b2/b3 loop region of tPHD2 (Dd > 1, ESI Fig. 7E†) are observed,
revealing large conformational changes in this region on
substrate binding.27 CP binding prior to the addition of CODD
did not signicantly alter the 1H–15N HSQC of tPHD2:CODD (ESI
Fig. 7E†). The weighted chemical shis mapped onto a crystal
structure of the PHD2$CODD complex (PDB 3HQR) show the
largest shis to cluster on the opposite face of the protein to the
substrate in the same manner as in apo-PHD2 binding (Fig. 3C),
further supporting binding of CPs, away from the active site,
including in the presence of CODD substrate.This journal is © The Royal Society of Chemistry 2018Consistent with this proposal, the binding affinity of CODD
for tPHD2, as determined by BLI, was comparable in the
absence (KD¼ 5.2 0.5 mM) and presence (KD¼ 6.3 0.3 mM) of
3C (Fig. 3D and ESI Fig. 8†), indicating that 3C does not
signicantly affect the PHD2:CODD interaction. The non-active
site nature of the binding was further supported by non-
denaturing mass spectrometric analysis of tPHD2, indicating
the CPs do not compete with Fe(II), FG2216 (a clinically trialled
2OG competitive PHD2 inhibitor)28 or substrate (CODD) (ESI
Fig. 9†). 3C binding to tPHD2 was abolished under denaturing
conditions (ESI Fig. 4†), indicating that the three-dimensional
structural fold of tPHD2 is important in CP recognition. Size-
exclusion chromatography multi-angle light scattering (SEC-
MALS) showed monomeric tPHD2 to bind to 3C (ESI Fig. 10†).Identication of key interactions of 3C/4C binding.
We next explored the molecular basis for the slow-dissociation
kinetics of 3C. A linearised variant of 3C showed very little
binding response towards tPHD2HisBio at 3 mM, indicating that the
cyclic conformation is important for tight binding affinity (ESI
Fig. 3†). We hypothesised that Arg12 of the CPsmay be important,Chem. Sci., 2018, 9, 4569–4578 | 4571
Fig. 3 NMR reveals binding of CPs to PHD2. (A) 1H–15N HSQC of tPHD2 in the presence (red) and absence (blue) of 3C. 1H and 15N chemical shift
changes were combined to give a Dd value, and assignments weremade using nearest neighbour assignment method. (B and C) Ribbons (above)
and surface (below) representations of chemical shift changes mapped on the “open” form of PHD2 (B), and the “closed” form complexed with
CODD (C) crystal structures, shown in two orientations. The substrate binding cleft and the active site are on the opposite face of the protein
where most of the residues with changes in chemical shift cluster on 3C binding. Structures used: (B) PDB (2G19) PHD2$Fe(II)$N-[(4-hydroxy8-
iodoisoquinoline-3-yl)carbonyl]glycine, (C) PDB : 3HQR, PHD2$Mn(II)$NOG$CODD. Colours: metal (green), small molecule inhibitors (magenta),
CODD (blue). (D) Weighted change in chemical shifts for different combinations of PHD2, CODD and 3C overlaid on the secondary structure of
tPHD2 (2G19) (see ESI†methods for details). KD values were determined using BLI (ESI Fig. 3 and 8†). Shift changes coloured according to theirDd
(heat map); Dd < 0.05 ppm (cyan) was considered to be insignificant; no colour indicates unassigned/unassignable residues.
4572 | Chem. Sci., 2018, 9, 4569–4578 This journal is © The Royal Society of Chemistry 2018
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View Article Onlinenot only from its absolute conservation in the selected CPs
(Fig. 1B), but also because Arg can formmultiple hydrogen bonds
and hydrophobic interactions enabling fold stabilisation. Substi-
tution of the Arg12 to Ala in 3C reduced target affinity by over
1000-fold (KD ¼ 783 nM) with a signicant decrease in t1/2 from
hours to seconds (ESI Fig. 3†), conrming that Arg12 is crucial forFig. 4 Development of 3CBt as a PHD2 capture probe to isolate endoge
biotin () and mixed with streptavidin-conjugatedmagnetic beads. After
heat denaturation and separated by SDS-PAGE. Quantities used in eac
marker, ‘IN’: 10-fold dilution (relative to the pull down sample) of the in
stained gels, (D)–(G) are western blots. (A) Recombinant tPHD2. (B) Reco
48.1, 29.4 and 42.3 kDa respectively). The input was diluted 16, 32 and 64-
U2OS cell lysate spiked with recombinant proteins. (D) Endogenous lev
PHD2 and PHD3 from Hep3B cell lysates under different oxygen concen
added recombinant PHD2. (G) Isolation of endogenous levels of the PHD
a blots, longer exposures excluding the most concentrated input lane are
and pull down samples to exclude the possibility of leakage between la
sample.
This journal is © The Royal Society of Chemistry 2018potent binding of the CPs to PHD2. Slow dissociation is oen
associated with conformational change of protein induced by
ligand-binding.29 The dramatic shi in the t1/2 may be indicative
of changes in the conformation of tPHD2 that ‘lock’ the CP–
enzyme complex (consistent with the NMR 1H–15N HSQC results).nous protein complexes. Samples were incubated with 3CBt (+) or with
a series of washing steps, proteins bound to the beads were released by
h experiment are listed in ESI Table 3.† ‘M’: molecular weight protein
put sample(s), ‘S’: supernatant, ‘PD’: pull down. (A)–(C) are Coomassie
mbinant full-length PHD1, 2, 3 and FIH (with molecular weights of 45.7,
fold and the supernatant 16-fold relative to the pull-down samples. (C)
els of PHD2 from hypoxic (1% O2) Hep3B cell lysates. (E) Pull down of
trations. (F) Dose-dependent capture of HIF1-a from RCC4 cells using
.HIF1a complex by 3CBt from RCC4 cells grown in hypoxia. For HIF1-
shown. An additional lane of markers was included between the inputs
nes. The input was diluted 10- and 100-fold relative to the pull down
Chem. Sci., 2018, 9, 4569–4578 | 4573
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View Article OnlineDevelopment of affinity capture probe for PHDs
Since 3C had a very high affinity (KD < nM) with slow dissociation
kinetics for PHD2 whilst not disrupting substrate binding, we
explored its potential as an affinity-based probe for substrate
capture. We synthesised a derivative of 3C with the (GlySer)3
spacer with an azido norleucine residue at the C-terminus (3CAz),
which would allow versatility in subsequent modications (e.g.
biotin, uorescence conjugation). This was then coupled to
a biotin derivative with an ethylene glycol linker and a bicyclo-
nonyne moiety in a strain-promoted azide–alkyne cycloaddition30
to generate 3CBt (ESI Fig. 11†). To test 3CBt as a capture probe,
isolated recombinant tPHD2 was incubated with 3CBt, then
precipitated using streptavidin-conjugated magnetic beads. High
levels of tPHD2 recovery were observed as judged by analysis of
the captured proteins by Coomassie-stained SDS-PAGE, with no
recovery of tPHD2 using biotin alone (Fig. 4A). A similar pull-
down experiment was carried out with recombinant full-length
PHD2 and its related isoforms, PHD1 and PHD3, as well as
FIH. PHD2 was recovered in a 3CBt-dependent manner (Fig. 4B)
indicating that the 3CBt probe maintained its affinity for the full-
length multi-domained PHD2. Interestingly, the probe was also
able to capture full length PHD1 and PHD3, but not FIH
(consistent with BLI experiments (Fig. 2)), suggesting that the 3C
binding region is conserved across the PHDs, but not in FIH.
Sequence alignments in the light of the NMR results suggest that
changes in the conserved b1/a3 (residues 206–215) region of the
PHDs (which differs in FIH) is likely involved in CP binding (ESI
Fig. 12†).
Next, we tested whether 3CBt can capture PHD2 from cell
lysates. When recombinant PHD2 (truncated or full length) was
added to U2OS cell lysates, both forms of PHD2 were recovered
using 3CBt while no recovery was observed with beads alone
(Fig. 4C). We next tested whether 3CBt can purify endogenous
PHD2 from cell lysates. PHD2 expression levels vary signi-
cantly across different cell types and are typically relatively low
in normoxia. However, both PHD2 and PHD3 protein produc-
tion is induced by hypoxia.31Hep3b cells, which have a relatively
high amount of endogenous PHD2 levels in normoxia
compared to other cell lines,31 were grown under hypoxic (1%
O2) conditions for 20 to 24 h for endogenous (hypoxia induced)
PHD capture. Following lysis and affinity-capture with 3CBt,
western blot analysis revealed that endogenous levels of PHD2
could be captured from cell lysates in a 3CBt-dependent manner
(Fig. 4D). Further detailed immunoblotting analysis of nor-
moxia and hypoxia-treated samples probed for hypoxia related
proteins (HIF1-a, PHD2 and PHD3) showed the expected upre-
gulation of these proteins in hypoxia over normoxia.31 3CBt was
able to affinity purify endogenous levels of PHD2 from cells
grown under both conditions, and PHD3 under hypoxic
conditions (endogenous PHD3 under normoxia is at very low
levels in Hep3b) (Fig. 4E). PHD1 is not highly expressed in
Hep3B cells and, could not be detected in the input cell lysate
(data not shown).21
Unlike active-site probes, 3CBt binds in a region away from
the active site, preserving the enzyme:substrate interactions, as
demonstrated by CODD binding and activity studies with 3C4574 | Chem. Sci., 2018, 9, 4569–4578(Fig. 2D and 3D). Thus, we explored the potential of 3CBt to
capture enzyme:substrate/ligand (i.e. PHD:HIF) complexes.
VHL-decient RCC4 cells, wherein HIF1-a is constitutively sta-
bilised and abundant,32 were used to test whether 3CBt can be
used to co-purify the PHD2:HIF1-a complex. When recombi-
nant PHD2 was spiked into RCC4 cell lysates and precipitated
using 3CBt, cellular HIF1-a co-puried with PHD2, in a PHD2
concentration-dependent manner (Fig. 4F). Furthermore, 3CBt
could co-purify HIF1-a and PHDs at endogenous levels, when
using RCC4 cells in hypoxia (Fig. 4G). This result demonstrates
the utility of 3CBt as an affinity-based probe for native
PHD:substrate complex pull-down. Interestingly, the co-
puried HIF1-a from RCC4 cells in hypoxia was (at least,
partially) hydroxylated at CODD (as shown by western blotting
for Pro564-OH specic antibody). This observation implies that
PHD2 can both catalyse hydroxylation of HIF1-a during the pull-
down process, which was carried out at normal atmospheric
oxygen levels, and bind hydroxylated HIF1-a. It is consistent
with prior work33,34 and with the activity assays carried out with
recombinant PHD2 (Fig. 2D). 3CBt binding thus, not only
maintains the catalytic activity of PHD2, but is also useful for co-
purifying both substrate and product complexes of PHD2. No
signicant effects on cell proliferation or PHD2 activity were
observed when RCC4 cells were dosed with CPs at different
oxygen gradients (0.1%, 5% and 21% O2, ESI Fig. 13†). While
this may be, in part, due to cell penetration/stability issues, it
suggests that CPs may be useful starting points for probe
development to study PHD activity and interactions in cells.
Discussion
The RaPID selection method enables fast and efficient
screening (weeks) of highly diverse (>1012) CP sequences and
generation of high-affinity binders against protein targets.35 We
used the RaPID selection to identify CPs binding to PHD2 with
KD values in the low- to sub-nM range, with comparable affini-
ties to antibody–antigen interactions.36 While the CPs were high
affinity binders, they were neither inhibitors nor substrates of
PHD2 (within limits of detection). Both cyclisation and the
highly conserved arginine residue at position 12 were important
in maintaining tight-binding characteristics of the CPs.
Biophysical analyses revealed that CPs and substrate CODD
binding to tPHD2 are not mutually exclusive, with CODD
binding and hydroxylation by PHD2 being unaffected by CP
binding. The CP (3C/4C) binding sites mapped using 1H–15N
NMR support the proposed binding mode; the CPs likely bind
on the opposite face to which HIF-a ODD substrates bind at the
active site pocket, in a relatively ‘at’ surface of the protein.
PHD2 undergoes dynamic conformational change upon
substrate binding, with themovement of the b2/b3 loop from an
extended position in the apo- form to a ‘closed’ conformation,
whereby the loop occludes the active site and interlocks
CODD.27,37 NMR analyses show that 3C tightly binds to PHD2
without substantially disrupting its conformational dynamics
or catalytic function. CP binding was selective for all three
human PHD isoforms (PHD1-3) compared to that for the other
tested human 2OG oxygenases, FIH and KDM4A. The region ofThis journal is © The Royal Society of Chemistry 2018
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View Article OnlinePHD2 interacting with CPs is likely to be relatively conserved
across the three PHD isoforms, assuming they have similar
structures since all three PHDs are able to bind to CP (3C).
While 3C, in particular, provides a unique pan-PHD recognition
tool, further studies on structure-activity-relationship of peptide
sequences may allow for ne-tuning for isoform selectivity,
based on the evidence that active site isoform selective CPs can
be achieved for other 2OG oxygenases20 and other enzyme
families.17–19
Interestingly, many reported CPs discovered through the
RaPID selection technique or similar methodologies inhibit
their enzyme targets.17,18,20,38 By way of example, with another
human 2OG oxygenase, the JmjC-domain containing histone
demethylase KDM4A, we identied potent active site targeting
inhibitors using the same type of procedure.20 The size and the
accessibility/plasticity of the active-site pockets of the target
proteins likely inuence the outcome of the favoured binding
modes of the enriched peptides during the screen. KDM4A, with
a more open substrate-binding pocket, however, shows little
conformational change upon its substrate histone peptide
binding. By contrast with KDM4A and FIH, PHD2 has a rela-
tively narrow substrate-binding pocket, with dynamic confor-
mational changes being observed upon HIF-a ODD binding (by
NMR and crystallography),37 possibly limiting CP access to the
active site during screening, and favouring non-active site
binding CPs. Thus, in order to use the RaPID system for iden-
tifying non-active site binders, in some cases, it may be bene-
cial to block the active site region, by using substrates/
inhibitors (which could be active site binding CPs).
To explore application of the high affinity and selectivity of
CPs in biological assays, we generated a biotin-linked affinity
probe for the PHDs, which was able to capture full-length
recombinant PHD1-3, as well as endogenously expressed
PHD2 and PHD3 from cell lysates. Importantly, 3CBt was also
able to pull down HIF1-a, conrming its ability to isolate
enzyme–substrate (or product) complexes. Many active-site
binding probes incorporate reactive electrophilic/nucleophilic
‘warheads’ or photoactive groups to covalently link to their
target protein for efficient target protein pull-down, including
those reported for PHD2.39–41 The high affinity of the 3CBt
peptide apparently avoids a requirement for such covalent
linkage for efficient pull-down, and the nature of the CP inter-
action which preserves the enzyme:substrate complex provides
signicant potential as a tool to study interacting partners for
PHDs.
As CPs are readily synthesised by solid phase peptide
synthesis, they can constitute a cheaper, more efficient and
reproducible alternative to current protein-based affinity
reagents. Indeed, during this study, independent batches of 3C
were synthesised and conrmed to have the same binding
affinities to PHD2, demonstrating the robustness and repro-
ducibility of manufacturing CPs. The CPs targeting PHDs only
recognised the folded conformation of PHD2 (ESI Fig. 4†),
which is useful for intact protein affinity studies. The confor-
mational recognition also suggests CPs that recognise, and
potentially stabilise, specic folds could be produced. Further-
more, due to their relative small size (2 kDa) and syntheticThis journal is © The Royal Society of Chemistry 2018tractability compared to antibodies, CPs offer the potential for
engineering to enable labelling or targeting applications.
In addition to CPs use for enzyme:substrate complex
capture, our work demonstrates the ability of RaPID selection to
generate highly potent, tight binding CPs to a relatively at
protein surface. The results thus imply that exploring RaPID
generated CPs as new modalities for targeting protein surfaces
lacking distinct binding pockets, as present in many PPI sites,
will be productive.12,42 While it is yet unknown if the identied
region is the site of a biologically relevant for PPI for the HIF
hydroxylases, CPs can be used to probe such questions. CPs can
further be used as assay development tools, or as starting points
for designing drug-like compounds targeting specic PPI sites.
The combined results with RaPID generated CPs suggest they
have tremendous general potential in functional studies and for
enabling drug discovery involving PPIs.Conclusions
In conclusion, we have demonstrated the potential of the RaPID
methodology for the generation of highly potent non-
modulatory, non-active site binding CP probes as exemplied
for the human PHD oxygenase subfamily. The results reveal that
the CP probes can be designed to bind with sub-nanomolar
affinity and selectivity on protein surfaces. Such binding CPs
can have valuable applications, as demonstrated by the devel-
opment of CPs as affinity probes for enzyme–substrate complex
capture. Thus, we propose CPs have substantial potential to be
developed as powerful, targeted tools for probing proteins and
their interaction partners.Experimental details
Full experimental procedures are detailed in the ESI;†
a summary of key experimental methods is given below.Materials and methods
Production of recombinant proteins
Recombinant forms of tPHD2, tPHD2HisBio,
15N-tPHD2, PHD3,
FIH and KDM4A were produced in Escherichia coli BL21 (DE3)
cells. Full-length PHD1 and PHD2 were produced by baculovi-
rus infection of Sf9 insect cells.Screening of tPHD2 using RaPID system
Flexizyme RNA, tRNAfMetCAU and ClAc-
DTyr-tRNAfMetCAU were
prepared as reported.17,43 Translation factors, enzymes and
ribosome were prepared and mixed as described44–46 giving
a modied in vitro translation system used for reprogramming
of translation initiation.17,47 The puromycin-fused (NNK)4–12
mRNA library was prepared by in vitro transcription.18 The in
vitro selection of CPs binding to tPHD2HisBio was carried out
using RaPID system,18 but with minor modications as outlined
in the ESI.†Chem. Sci., 2018, 9, 4569–4578 | 4575
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View Article OnlineIllumina sequencing
To construct an Illumina-compatible sequencing library from
the DNA sequences recovered aer selection, specic forward
(P5) and reverse (P7) primers (ESI Table 4†) were designed
containing priming sequences complementary to the constant
region of the recovered DNA at the 30 end of the primer and
incorporating adaptor sequences necessary for sequencing at
the 50 end (ESI Fig. 14†). Each amplied PCR product was
quantitated using a high sensitivity DNA tape on the Tapesta-
tion 2000 (Agilent) prior to pooling and nal quantication of
the library was performed by quantitative PCR using pre-diluted
standards (Kapa Biosystems). Paired-end sequencing was per-
formed using a NextSeq 500 (Illumina) with 80 reads in each
direction.Logo plots
Illumina next generation sequencing data from R5 was used to
construct logo plots using WebLogo (http://
weblogo.berkeley.edu/logo.cgi)25 for 14 mer sequences present
at a level of $0.01% (256 different peptides).Biolayer interferometry
Experiments were performed using an OctetRed 384 (ForteBio).
Protein was loaded onto the biosensors, the sensors were then
subjected to cycles of association/dissociation with a dilution
series of peptides. To correct for dri, each experiment included
a DMSO only control, the data from which was subtracted from
the other sensors and the data globally t using the ForteBio
Data Analysis soware (v9.0.0.4).Chemical synthesis of selected macrocyclic peptides
CP linear precursors were prepared with an amidated C-
terminus by standard Fmoc-solid phase synthesis and the N-
terminus chloroacetylated. The peptides were cleaved from
the resin with a TFA-based cleavage mixture, cyclised, then
puried by HPLC. Peptide concentrations were determined
using 1H NMR with an internal standard of 3-(trimethylsilyl)
propionic-2,2,3,3-d4 acid.PHD2 enzyme activity assays
CODDmut was used for activity assays to avoid the formation of
non-specic methionine oxidation products, which could also
exhibit a +16 Da mass shi. Comparisons showed activity
equivalent to the ‘natural’ substrate peptide (data not shown).
Aer a suitable reaction time, samples were quenched with 1%
(v/v) aqueous formic acid and analysed by Matrix Assisted Laser
Desorption/Ionization-Time of Flight (MALDI-TOF) mass-
spectrometry. Relative peak intensities of starting material/
product were used to calculate level of enzymatic activity.NMR experiments
NMR spectra were recorded using a Bruker AVIII 700 MHz NMR
spectrometer equipped with a 5 mm inverse cryoprobe using
3 mm MATCH NMR tubes (Cortectnet). Weighted amide4576 | Chem. Sci., 2018, 9, 4569–4578chemical shi changes (Dd, in ppm) were determined using eqn
(1).48 Protein chemical shi assignments for tPHD2 have been
previously reported.27
Dd ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðDd1HÞ2 þ

Dd15N
10
2s
(1)
Capture assays
Cell pellets were lysed using freshly prepared lysis buffer.
Lysates were then portioned and recombinant proteins added
as required. These solutions were then further divided; one
portion added to a solution of 3CBt e.g. 1 mM in DMSO to give
a nal 3CBt concentration of 10 mM (1% (v/v) DMSO) and the
other added to the same volume of biotin (1 mM in DMSO). The
solutions were allowed to equilibrate on ice for 1 h before
transfer of the entire solution to another tube containing pre-
washed, and pelleted Dynabeads® M-280 Streptavidin (Life-
technologies, #11205D). The resultant suspensions were incu-
bated at 4 C for 1 h with gentle mixing before the beads were
pelleted using a magnet and washed: once with 1 vol of lysis
buffer and twice with 1 vol TBST (50 mM Tris–HCl (pH 7.5 at 22
C), 200 mM NaCl, 0.05% (v/v) Tween-20) with the suspension
being transferred to a new tube with the second TBST wash. The
beads were resuspended in SDS-PAGE loading buffer, heated to
95 C for 5 min, and the supernatant recovered. Samples were
then separated by SDS-PAGE and either stained with instant
blue (Expedeon #ISB1L) or transferred to a polyvinylidene
diuoride PVDF membrane (Millipore Immobilon-P
#IPVH00010). Antibodies were used at 1 : 1000 (v/v) dilution
for immunoblotting and were as follows: pan-anti-HIF-1a (clone
54, BD Transduction Laboratories™), anti-HIF-1a Hyp402
(catalogue number 07-1585, Merck Millipore), anti-HIF-1a
Hyp564 (D43B5, Cell Signalling), anti-HIF-1a HyN803 (a
generous gi from Lee et al.49), HRP-conjugated anti-b-actin
(clone AC15, Abcam), and anti-PHD2/PHD3 as reported.31
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